These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 31128829)

  • 1. The use of natural language processing to identify Tdap-related local reactions at five health care systems in the Vaccine Safety Datalink.
    Zheng C; Yu W; Xie F; Chen W; Mercado C; Sy LS; Qian L; Glenn S; Lee G; Tseng HF; Duffy J; Jackson LA; Daley MF; Crane B; McLean HQ; Jacobsen SJ
    Int J Med Inform; 2019 Jul; 127():27-34. PubMed ID: 31128829
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The use of natural language processing to identify vaccine-related anaphylaxis at five health care systems in the Vaccine Safety Datalink.
    Yu W; Zheng C; Xie F; Chen W; Mercado C; Sy LS; Qian L; Glenn S; Tseng HF; Lee G; Duffy J; McNeil MM; Daley MF; Crane B; McLean HQ; Jackson LA; Jacobsen SJ
    Pharmacoepidemiol Drug Saf; 2020 Feb; 29(2):182-188. PubMed ID: 31797475
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immunogenicity and safety of reduced-antigen tetanus, diphtheria and acellular pertussis vaccination in adults treated for obstructive airway diseases.
    Van den Steen P; Cheuvart B; Deraedt Q; Valdes Verelst L; Shamarina D
    Hum Vaccin Immunother; 2023 Dec; 19(1):2159731. PubMed ID: 36746754
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Preventing tetanus, diphtheria, and pertussis among adolescents: use of tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccines recommendations of the Advisory Committee on Immunization Practices (ACIP).
    Broder KR; Cortese MM; Iskander JK; Kretsinger K; Slade BA; Brown KH; Mijalski CM; Tiwari T; Weston EJ; Cohn AC; Srivastava PU; Moran JS; Schwartz B; Murphy TV;
    MMWR Recomm Rep; 2006 Mar; 55(RR-3):1-34. PubMed ID: 16557217
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A genetically inactivated two-component acellular pertussis vaccine, alone or combined with tetanus and reduced-dose diphtheria vaccines, in adolescents: a phase 2/3, randomised controlled non-inferiority trial.
    Sricharoenchai S; Sirivichayakul C; Chokephaibulkit K; Pitisuttithum P; Dhitavat J; Pitisuthitham A; Phongsamart W; Boonnak K; Lapphra K; Sabmee Y; Wittawatmongkol O; Chinwangso P; Poredi IK; Petre J; Thai PH; Viviani S
    Lancet Infect Dis; 2018 Jan; 18(1):58-67. PubMed ID: 29066131
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A randomised, double-blind, non-inferiority clinical trial on the safety and immunogenicity of a tetanus, diphtheria and monocomponent acellular pertussis (TdaP) vaccine in comparison to a tetanus and diphtheria (Td) vaccine when given as booster vaccinations to healthy adults.
    Thierry-Carstensen B; Jordan K; Uhlving HH; Dalby T; Sørensen C; Jensen AM; Heilmann C
    Vaccine; 2012 Aug; 30(37):5464-71. PubMed ID: 22776216
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Reduced-antigen, combined diphtheria, tetanus and acellular pertussis vaccine, adsorbed (Boostrix®): a review of its properties and use as a single-dose booster immunization.
    McCormack PL
    Drugs; 2012 Sep; 72(13):1765-91. PubMed ID: 22931522
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Safety and immunogenicity of a combined Tetanus, Diphtheria, recombinant acellular Pertussis vaccine (TdaP) in healthy Thai adults.
    Sirivichayakul C; Chanthavanich P; Limkittikul K; Siegrist CA; Wijagkanalan W; Chinwangso P; Petre J; Hong Thai P; Chauhan M; Viviani S
    Hum Vaccin Immunother; 2017 Jan; 13(1):136-143. PubMed ID: 27686283
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prevention of pertussis among adolescents: recommendations for use of tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis (Tdap) vaccine.
    America Academy of Pediatrics Commitee on Infectious Diseases
    Pediatrics; 2006 Mar; 117(3):965-78. PubMed ID: 16382131
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Reactogenicity and immunogenicity of tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis vaccine (Tdap) in pregnant and nonpregnant women.
    Fortner KB; Swamy GK; Broder KR; Jimenez-Truque N; Zhu Y; Moro PL; Liang J; Walter EB; Heine RP; Moody MA; Yoder S; Edwards KM
    Vaccine; 2018 Oct; 36(42):6354-6360. PubMed ID: 30219367
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Safety and immunogenicity of SIIPL Tdap, a new tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccine, in healthy subjects 4-65 years of age: A Phase II/III randomized, observer-blinded, active controlled, multicenter clinical study in Germany.
    Aydin I; May M; Pisano F; Mpofu-Maetzig N; Grode L; Parekh S; Pujari P; Shewale S; Desai S; Sharma H; Rao H; Gautam M; Gairola S; Shaligram U
    Vaccine; 2023 Nov; 41(46):6810-6819. PubMed ID: 37827966
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tdap vaccination during pregnancy and risk of chorioamnionitis and related infant outcomes.
    Greenberg V; Vazquez-Benitez G; Kharbanda EO; Daley MF; Fu Tseng H; Klein NP; Naleway AL; Williams JTB; Donahue J; Jackson L; Weintraub E; Lipkind H; DeSilva MB
    Vaccine; 2023 May; 41(22):3429-3435. PubMed ID: 37117057
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Impact of tetanus, diphtheria, and acellular pertussis (Tdap) vaccine use in wound management on health care costs and pertussis cases.
    Talbird SE; Graham J; Mauskopf J; Masseria C; Krishnarajah G
    J Manag Care Spec Pharm; 2015 Jan; 21(1):88-99, 99a-c. PubMed ID: 25562776
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Assessment of safety and efficacy against Bordetella pertussis of a new tetanus-reduced dose diphtheria-acellular pertussis vaccine in a murine model.
    Kwon HJ; Han SB; Kim BR; Kang KR; Huh DH; Choi GS; Ahn DH; Kang JH
    BMC Infect Dis; 2017 Apr; 17(1):247. PubMed ID: 28376777
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A modified vaccine reduces the rate of large injection site reactions to the preschool booster dose of diphtheria-tetanus-acellular pertussis vaccine: results of a randomized, controlled trial.
    Scheifele DW; Halperin SA; Ochnio JJ; Ferguson AC; Skowronski DM
    Pediatr Infect Dis J; 2005 Dec; 24(12):1059-66. PubMed ID: 16371866
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immunogenicity and safety of a second booster dose of an acellular pertussis vaccine combined with reduced antigen content diphtheria-tetanus toxoids 10 years after a first booster in adolescence: An open, phase III, non-randomized, multi-center study.
    Kovac M; Kostanyan L; Mesaros N; Kuriyakose S; Varman M
    Hum Vaccin Immunother; 2018; 14(8):1977-1986. PubMed ID: 29630439
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A 6-year Prospective, Observational, Multi-Center Post-Marketing Surveillance of the Safety of Tetanus Toxoid, Reduced Diphtheria Toxoid, and Acellular Pertussis (Tdap) Vaccine in Korea.
    Park HJ; Kim SJ; Song R; Chen J; Kim JH; Devadiga R; Kang HC
    J Korean Med Sci; 2019 Apr; 34(12):e105. PubMed ID: 30940999
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Randomized Controlled Trial of the Safety and Immunogenicity of Revaccination With Tetanus-Diphtheria-Acellular Pertussis Vaccine (Tdap) in Adults 10 Years After a Previous Dose.
    Halperin SA; Donovan C; Marshall GS; Pool V; Decker MD; Johnson DR; Greenberg DP;
    J Pediatric Infect Dis Soc; 2019 May; 8(2):105-114. PubMed ID: 29438562
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Safety and immunogenicity of an indigenously developed tetanus toxoid, diphtheria toxoid, and acellular pertussis vaccine (Tdap) in adults, adolescents, and children in India.
    Sharma HJ; Parekh S; Pujari P; Shewale S; Desai S; Kawade A; Ravi M; Oswal J; James S; Mahantashetti N; Munshi R; Ghosh A; Rao V; Balsubramaniam S; Varughese P; Somshekhar A; Ginsburg AS; Rao H; Gautam M; Gairola S; Shaligram U
    Expert Rev Vaccines; 2023; 22(1):278-287. PubMed ID: 36883291
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antibody persistence and safety and immunogenicity of a second booster dose nine years after a first booster vaccination with a reduced antigen diphtheria-tetanus-acellular pertussis vaccine (Tdap) in adults.
    Brandon D; Kimmel M; Kuriyakose SO; Kostanyan L; Mesaros N
    Vaccine; 2018 Oct; 36(42):6325-6333. PubMed ID: 30197282
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.